vs
博士伦（BLCO）与Toast, Inc.（TOST）财务数据对比。点击上方公司名可切换其他公司
Toast, Inc.的季度营收约是博士伦的1.2倍（$1.6B vs $1.4B），Toast, Inc.净利率更高（6.2% vs -4.1%，领先10.3%），Toast, Inc.同比增速更快（22.0% vs 9.8%），Toast, Inc.自由现金流更多（$178.0M vs $60.0M），过去两年Toast, Inc.的营收复合增速更高（23.3% vs 13.1%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
Toast, Inc.是总部位于美国马萨诸塞州波士顿的云餐饮管理软件企业，主打基于安卓操作系统研发的一体化销售点（POS）系统，可为餐饮商家提供涵盖收银、订单管理等在内的全场景门店经营解决方案。
BLCO vs TOST — 直观对比
营收规模更大
TOST
是对方的1.2倍
$1.4B
营收增速更快
TOST
高出12.3%
9.8%
净利率更高
TOST
高出10.3%
-4.1%
自由现金流更多
TOST
多$118.0M
$60.0M
两年增速更快
TOST
近两年复合增速
13.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.6B |
| 净利润 | $-58.0M | $101.0M |
| 毛利率 | — | 25.9% |
| 营业利润率 | 8.0% | 5.2% |
| 净利率 | -4.1% | 6.2% |
| 营收同比 | 9.8% | 22.0% |
| 净利润同比 | -1833.3% | 215.6% |
| 每股收益（稀释后） | $-0.16 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOTOST
| Q4 25 | $1.4B | $1.6B | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.1B | $1.1B |
净利润BLCOTOST
| Q4 25 | $-58.0M | $101.0M | ||
| Q3 25 | $-28.0M | $105.0M | ||
| Q2 25 | $-62.0M | $80.0M | ||
| Q1 25 | $-212.0M | $56.0M | ||
| Q4 24 | $-3.0M | $32.0M | ||
| Q3 24 | $4.0M | $56.0M | ||
| Q2 24 | $-151.0M | $14.0M | ||
| Q1 24 | $-167.0M | $-83.0M |
毛利率BLCOTOST
| Q4 25 | — | 25.9% | ||
| Q3 25 | — | 26.5% | ||
| Q2 25 | — | 25.3% | ||
| Q1 25 | — | 25.9% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | — | 24.7% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 23.2% |
营业利润率BLCOTOST
| Q4 25 | 8.0% | 5.2% | ||
| Q3 25 | 7.4% | 5.1% | ||
| Q2 25 | -0.9% | 5.2% | ||
| Q1 25 | -7.3% | 3.2% | ||
| Q4 24 | 6.8% | 2.5% | ||
| Q3 24 | 3.6% | 2.6% | ||
| Q2 24 | 2.1% | 0.4% | ||
| Q1 24 | 0.5% | -5.2% |
净利率BLCOTOST
| Q4 25 | -4.1% | 6.2% | ||
| Q3 25 | -2.2% | 6.4% | ||
| Q2 25 | -4.9% | 5.2% | ||
| Q1 25 | -18.6% | 4.2% | ||
| Q4 24 | -0.2% | 2.4% | ||
| Q3 24 | 0.3% | 4.3% | ||
| Q2 24 | -12.4% | 1.1% | ||
| Q1 24 | -15.2% | -7.7% |
每股收益（稀释后）BLCOTOST
| Q4 25 | $-0.16 | $0.18 | ||
| Q3 25 | $-0.08 | $0.16 | ||
| Q2 25 | $-0.18 | $0.13 | ||
| Q1 25 | $-0.60 | $0.09 | ||
| Q4 24 | $-0.00 | $0.09 | ||
| Q3 24 | $0.01 | $0.07 | ||
| Q2 24 | $-0.43 | $0.02 | ||
| Q1 24 | $-0.48 | $-0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $1.4B |
| 总债务越低越好 | $5.0B | — |
| 股东权益账面价值 | $6.4B | $2.1B |
| 总资产 | $14.0B | $3.1B |
| 负债/权益比越低杠杆越低 | 0.78× | — |
8季度趋势，按日历期对齐
现金及短期投资BLCOTOST
| Q4 25 | $383.0M | $1.4B | ||
| Q3 25 | $310.0M | $1.4B | ||
| Q2 25 | $266.0M | $1.2B | ||
| Q1 25 | $202.0M | $1.0B | ||
| Q4 24 | $305.0M | $903.0M | ||
| Q3 24 | $329.0M | $761.0M | ||
| Q2 24 | $285.0M | $691.0M | ||
| Q1 24 | $315.0M | $578.0M |
总债务BLCOTOST
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — | ||
| Q1 24 | $4.6B | — |
股东权益BLCOTOST
| Q4 25 | $6.4B | $2.1B | ||
| Q3 25 | $6.4B | $2.0B | ||
| Q2 25 | $6.4B | $1.8B | ||
| Q1 25 | $6.4B | $1.7B | ||
| Q4 24 | $6.5B | $1.5B | ||
| Q3 24 | $6.6B | $1.4B | ||
| Q2 24 | $6.5B | $1.3B | ||
| Q1 24 | $6.7B | $1.2B |
总资产BLCOTOST
| Q4 25 | $14.0B | $3.1B | ||
| Q3 25 | $13.8B | $3.0B | ||
| Q2 25 | $13.8B | $2.8B | ||
| Q1 25 | $13.4B | $2.6B | ||
| Q4 24 | $13.5B | $2.4B | ||
| Q3 24 | $13.5B | $2.2B | ||
| Q2 24 | $13.3B | $2.2B | ||
| Q1 24 | $13.3B | $2.1B |
负债/权益比BLCOTOST
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $194.0M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $178.0M |
| 自由现金流率自由现金流/营收 | 4.3% | 10.9% |
| 资本支出强度资本支出/营收 | 5.4% | 1.0% |
| 现金转化率经营现金流/净利润 | — | 1.92× |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $608.0M |
8季度趋势，按日历期对齐
经营现金流BLCOTOST
| Q4 25 | $136.0M | $194.0M | ||
| Q3 25 | $137.0M | $165.0M | ||
| Q2 25 | $35.0M | $223.0M | ||
| Q1 25 | $-25.0M | $79.0M | ||
| Q4 24 | $22.0M | $147.0M | ||
| Q3 24 | $154.0M | $109.0M | ||
| Q2 24 | $15.0M | $124.0M | ||
| Q1 24 | $41.0M | $-20.0M |
自由现金流BLCOTOST
| Q4 25 | $60.0M | $178.0M | ||
| Q3 25 | $63.0M | $153.0M | ||
| Q2 25 | $-54.0M | $208.0M | ||
| Q1 25 | $-135.0M | $69.0M | ||
| Q4 24 | $-70.0M | $134.0M | ||
| Q3 24 | $94.0M | $97.0M | ||
| Q2 24 | $-57.0M | $108.0M | ||
| Q1 24 | $-26.0M | $-33.0M |
自由现金流率BLCOTOST
| Q4 25 | 4.3% | 10.9% | ||
| Q3 25 | 4.9% | 9.4% | ||
| Q2 25 | -4.2% | 13.4% | ||
| Q1 25 | -11.9% | 5.2% | ||
| Q4 24 | -5.5% | 10.0% | ||
| Q3 24 | 7.9% | 7.4% | ||
| Q2 24 | -4.7% | 8.7% | ||
| Q1 24 | -2.4% | -3.1% |
资本支出强度BLCOTOST
| Q4 25 | 5.4% | 1.0% | ||
| Q3 25 | 5.8% | 0.7% | ||
| Q2 25 | 7.0% | 1.0% | ||
| Q1 25 | 9.7% | 0.7% | ||
| Q4 24 | 7.2% | 1.0% | ||
| Q3 24 | 5.0% | 0.9% | ||
| Q2 24 | 5.9% | 1.3% | ||
| Q1 24 | 6.1% | 1.2% |
现金转化率BLCOTOST
| Q4 25 | — | 1.92× | ||
| Q3 25 | — | 1.57× | ||
| Q2 25 | — | 2.79× | ||
| Q1 25 | — | 1.41× | ||
| Q4 24 | — | 4.59× | ||
| Q3 24 | 38.50× | 1.95× | ||
| Q2 24 | — | 8.86× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
TOST
| Technology Service | $1.3B | 82% |
| License | $256.0M | 16% |
| Product And Professional Services | $43.0M | 3% |
